High Tide Inc. announced that its U.S. hemp‑derived CBD subsidiary, NuLeaf Naturals, is pursuing participation in the newly launched Centers for Medicare & Medicaid Services (CMS) Beneficiary Engagement Incentive (BEI) pilot program. The pilot, which began on April 1 2026, allows Accountable Care Organizations and oncology practices to provide eligible hemp‑derived CBD products to Medicare beneficiaries at no cost, up to $500 per beneficiary per year.
The BEI pilot is part of a broader CMS effort to expand access to evidence‑based therapies for Medicare beneficiaries. It covers the ACO REACH Model and the Enhancing Oncology Model, with a planned expansion to the Long‑term Enhanced ACO Design (LEAD) Model in January 2027. Dr. Mehmet Oz, the CMS Administrator, confirmed the program’s launch.
NuLeaf’s product portfolio—USDA Certified Organic, THC‑free broad‑spectrum CBD—has been built to meet the program’s strict quality and compliance requirements. The company operates cGMP‑certified, FDA‑registered manufacturing facilities and has been actively engaging with participating organizations to secure supply agreements. While the exact number of agreements is not yet disclosed, NuLeaf is positioning itself to become a trusted supplier as the program expands.
For High Tide, the Medicare pilot represents a significant diversification of its U.S. revenue base beyond its Canadian retail operations. In Q1 2026, the company reported revenue of $178.3 million, up 25 % year‑over‑year, and a gross margin of 25 %. The growth reflects strong demand for its high‑quality cannabinoid products and the company’s ability to scale its supply chain. The Medicare opportunity could add a sizable, low‑cost revenue stream that complements the company’s existing product lines.
The pilot has attracted regulatory scrutiny, with some groups challenging the program in court on the grounds that it bypasses traditional FDA approval processes. High Tide’s management has emphasized that NuLeaf’s products meet all current regulatory standards and that the program is designed to provide safe, evidence‑based therapies to beneficiaries. The company’s CEO, Raj Grover, highlighted the strategic importance of the pilot in expanding access to hemp‑derived CBD while maintaining compliance.
Overall, the announcement signals a new growth avenue for High Tide and positions NuLeaf Naturals as a key player in the emerging Medicare CBD market. The company’s focus on regulatory compliance, quality, and strategic partnerships underpins its confidence that the pilot will translate into measurable revenue and broaden its customer base in the United States.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.